Lipid Disorder Treatment Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Drug Type (Lovastatin, Atorvastatin, Rosuvastatin, Others), By Distribution Channel (Online, Offline), And Geography - Forecasts From 2023 To 2028

The lipid disorder treatment market was valued at US$26.269 billion in 2021.

Lipids, or lipoproteins, are the fats found circulating in the bloodstream. Lipid disorders are a broad spectrum of metabolic conditions affecting blood lipid levels. They are generally characterized by elevated levels of cholesterol, triglycerides, and/or lipoproteins in the blood in association with an increased risk of (or current) cardiovascular disease. There are several easy ways to lower LDLs, including avoiding foods high in saturated fat, dietary cholesterol, and excess calories; exercising; maintaining a healthy weight; and stopping smoking. Statins are the most commonly prescribed treatments for lipid treatment.

Consumers' increasing adoption of unhealthy habits has increased various lifestyle diseases around the globe. The growing prevalence of high cholesterol levels and the increasing developments in treating lipid metabolism disorders will further augment the market growth. World Health Organization states that a third of ischemic heart disease is attributable to high cholesterol levels. Moreover, smoking and drinking have also contributed to the rising prevalence of lipid disorders, further fueling market growth.  

This research study examines the lipid disorder treatment market based on various segments: drug type, distribution channel, and geography. First, a brief market overview details key driving factors and challenges. Next, Porter's five forces model comprehensively analyzes the lipid disorder treatment industry. This is followed by industry value chain analysis which determines the companies which are part of the different processes and contributing to various sectors.

The study also presents in-depth information concerning the development, trends, and industry policies and regulations affecting the lipid disorder treatment market. Moreover, the research study analyzes the overall regulatory framework of the lipid disorder treatment sector, offering stakeholders a better understanding of the key factors influencing the overall market environment.

Lipid disorder treatment market – Forecasts from 2023 to 2028 is a comprehensive and latest report. It provides vital market information to executives and interested stakeholders to enable them to get vital market information. The report also analyzes the competitive landscape, details the strategies of key market players, and plots them on our vendor matrix in four quadrants: leader, follower, challenger, and niche.

The scope and coverage of the lipid disorder treatment market report is as below:

• Lipid disorder treatment market data tables and charts
• Market outlook with sections on drivers, restraints, Porter's, and industry value chain analysis
• Market assessment by drug type into lovastatin, atorvastatin, rosuvastatin, and others.
• Detailed market trends, analysis, and graphical representation by distribution channel into online and offline.
• A 360^o view of the lipid disorder treatment market across different geographies (North America, South America, Europe, Middle East and Africa, and Asia Pacific) with further breakdown for key countries within those regions.

Lipid Disorder Treatment Market Scope:

 

Report Metric	Details
Market Size Value in 2021	US$26.269 billion
Growth Rate	CAGR during the forecast period
Base Year	2021
Forecast Period	2023 – 2028
Forecast Unit (Value)	USD Billion
Segments Covered	Drug Type, Distribution Channel, and Geography
Regions Covered	North America, South America, Europe, Middle East and Africa, Asia Pacific
Companies Covered	Pfizer, Novartis AG, Merck & Co., Inc, Emcure Pharmaceuticals Ltd., Mylan Pharmaceuticals, Inc., Sun Pharma
Customization Scope	Free report customization with purchase

 

Different segments covered under the lipid disorder treatment market report are as below:

• By Drug Type
  • Lovastatin
  • Atorvastatin 
  • Rosuvastatin
  • Others 
• By Distribution Channel
  • Online
  • Offline 
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Israel
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Indonesia
    • Thailand
    • Others

---

1.  INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY  

2.1. Research Data

2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

5. LIPID DISORDER TREATMENT MARKET, BY DRUG TYPE

5.1. Introduction

5.2. Lovastatin

5.3. Atorvastatin 

5.4. Rosuvastatin

5.5. Others 

6. LIPID DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL

6.1. Introduction

6.2. Online

6.3. Offline 

7. LIPID DISORDER TREATMENT MARKET, BY GEOGRAPHY

7.1. Introduction

7.2. North America

7.2.1. United States

7.2.2. Canada

7.2.3. Mexico

7.3. South America

7.3.1. Brazil

7.3.2. Argentina

7.3.3. Others

7.4. Europe

7.4.1. United Kingdom

7.4.2. Germany

7.4.3. France

7.4.4. Spain

7.4.5. Others

7.5. Middle East and Africa

7.5.1. Saudi Arabia

7.5.2. UAE

7.5.3. Israel

7.5.4. Others

7.6. Asia Pacific

7.6.1. Japan

7.6.2. China

7.6.3. India

7.6.4. South Korea

7.6.5. Indonesia

7.6.6. Thailand

7.6.7. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

8.1. Major Players and Strategy Analysis

8.2. Emerging Players and Market Lucrativeness

8.3. Mergers, Acquisitions, Agreements, and Collaborations

8.4. Vendor Competitiveness Matrix

9. COMPANY PROFILES

9.1. Pfizer

9.2. Novartis AG

9.3. Merck & Co., Inc

9.4. Emcure Pharmaceuticals Ltd.

9.5. Mylan Pharmaceuticals, Inc.

9.6. Sun Pharma

Pfizer

Novartis AG

Merck & Co., Inc

Emcure Pharmaceuticals Ltd.

Mylan Pharmaceuticals, Inc.

Sun Pharma